The pharmaceutical giant Merck faces yet another FDA rejection of its anesthesia drug Sugammadex, FierceBiotech reports. Sugammadex, obtained when Merck merged with the pharmaceutical company Shering-Plough, has been hailed as one of the top experimental drugs in Merck’s development pipeline. Over the years, however, it has experienced a number of setbacks, beginning with its first rejection by the FDA in 2008 and continuing with a second ...
Merck Faces 3rd Rejection of Anesthesia Drug
Posted April 3, 2015 in Product News and Recalls
